Precision Medicine and Artificial Intelligence: The Perfect Fit for Autoimmunity
Editat de Michael Mahleren Limba Engleză Paperback – 16 mar 2021
More and more diagnostic products utilize AI, which is also starting to be supported by regulatory agencies such as the Food and Drug Administration (FDA). Knowledge generation by leveraging large datasets including demographic, environmental, clinical and biomarker data has the potential to not only impact the diagnosis of patients, but also disease prediction, prognosis and treatment options.
- Allows the readers to gain an overview on precision medicine for autoimmune diseases leveraging AI solutions
- Provides background, milestone and examples of precision medicine
- Outlines the paradigm shift towards precision medicine driven by value-based systems
- Discusses future applications of precision medicine research using AI
- Other aspects covered in the book include regulatory insights, data analytics and visualization, types of biomarkers as well as the role of the patient in precision medicine
Preț: 778.72 lei
Preț vechi: 1027.50 lei
-24% Nou
Puncte Express: 1168
Preț estimativ în valută:
149.04€ • 157.23$ • 124.20£
149.04€ • 157.23$ • 124.20£
Carte tipărită la comandă
Livrare economică 26 decembrie 24 - 09 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780128202395
ISBN-10: 0128202394
Pagini: 300
Dimensiuni: 152 x 229 x 18 mm
Greutate: 0.4 kg
Editura: ELSEVIER SCIENCE
ISBN-10: 0128202394
Pagini: 300
Dimensiuni: 152 x 229 x 18 mm
Greutate: 0.4 kg
Editura: ELSEVIER SCIENCE
Public țintă
The primary target audience for the planned book is the scientific community at the interface between medicine, biotechnology as well as computer science (i.e. Artificial Intelligence). From the readers profile perspective, the book targets scientist on academia and in biotech as well as in pharma industry (Translational Research and Biomarker Discovery groups. Small molecule / drug target discovery). Some of the highler level chapters in the book also target functional heads in the industry (e.g. Director / VP level).Cuprins
1. History, current status, and future directions of artificial intelligence
Olga Kubassova, Faiq Shaikh, Carlos Melus, and Michael Mahler
2. Precision medicine as an approach to autoimmune diseases
Marvin J. Fritzler and Michael Mahler
3. Biomarker and data science as integral part of precision medicine
Carlos Melus, Brenden Rossin, Mary Ann Aure, and Michael Mahler
4. Companion and complementary diagnostics: A key to precision medicine
Jan Trøst Jørgensen
5. Checkpoint inhibitors: Interface of cancer and autoimmunity: Opportunity for second level precision medicine
Savino Sciascia, Marie Hudson, Marvin J. Fritzler, Minoru Satoh, and Michael Mahler
6. The evolving potential of precision medicine in the management of autoimmune liver disease
Gary L. Norman, Nicola Bizzaro, Danilo Villalta, Diego Vergani, Giorgina Mieli-Vergani, Gideon M. Hirschfield, and Michael Mahler
7. Precision medicine in autoimmune disease
Kevin D. Deane
8. Development of multi-omics approach in autoimmune diseases
May Y. Choi, Marvin J. Fritzler, and Michael Mahler
9. N-of-1 trials: Implications for clinical practice and personalized clinical trials
Joanne Bradbury and Michael Mahler
10. Health risk assessment and family history: Toward disease prevention
Lily W. Martin, Lauren C. Prisco, Laura Martinez-Prat, Michael Mahler, and Jeffrey A. Sparks
11. Regulatory aspects of artificial intelligence and machine learning-enabled software as medical devices (SaMD)
Michael Mahler, Carolina Auza, Roger Albesa, Carlos Melus, and Jungen Andrew Wu
12. Precision medicine from the patient’s perspective: More opportunities and increasing responsibilities
Kim MacMartin-Moglia and Michael Mahler
Olga Kubassova, Faiq Shaikh, Carlos Melus, and Michael Mahler
2. Precision medicine as an approach to autoimmune diseases
Marvin J. Fritzler and Michael Mahler
3. Biomarker and data science as integral part of precision medicine
Carlos Melus, Brenden Rossin, Mary Ann Aure, and Michael Mahler
4. Companion and complementary diagnostics: A key to precision medicine
Jan Trøst Jørgensen
5. Checkpoint inhibitors: Interface of cancer and autoimmunity: Opportunity for second level precision medicine
Savino Sciascia, Marie Hudson, Marvin J. Fritzler, Minoru Satoh, and Michael Mahler
6. The evolving potential of precision medicine in the management of autoimmune liver disease
Gary L. Norman, Nicola Bizzaro, Danilo Villalta, Diego Vergani, Giorgina Mieli-Vergani, Gideon M. Hirschfield, and Michael Mahler
7. Precision medicine in autoimmune disease
Kevin D. Deane
8. Development of multi-omics approach in autoimmune diseases
May Y. Choi, Marvin J. Fritzler, and Michael Mahler
9. N-of-1 trials: Implications for clinical practice and personalized clinical trials
Joanne Bradbury and Michael Mahler
10. Health risk assessment and family history: Toward disease prevention
Lily W. Martin, Lauren C. Prisco, Laura Martinez-Prat, Michael Mahler, and Jeffrey A. Sparks
11. Regulatory aspects of artificial intelligence and machine learning-enabled software as medical devices (SaMD)
Michael Mahler, Carolina Auza, Roger Albesa, Carlos Melus, and Jungen Andrew Wu
12. Precision medicine from the patient’s perspective: More opportunities and increasing responsibilities
Kim MacMartin-Moglia and Michael Mahler